Sanjay M Sisodiya

List of Publications by Year
in descending order

175	13,863	34016 52	25716 108
papers	citations	h-index	g-index

193	193	193	19699
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The <scp>ENIGMAâ€Epilepsy</scp> working group: Mapping disease from large data sets. Human Brain Mapping, 2022, 43, 113-128.	1.9	47
2	A systemsâ€level analysis highlights microglial activation as a modifying factor in common epilepsies. Neuropathology and Applied Neurobiology, 2022, 48, .	1.8	22
3	Topographic divergence of atypical cortical asymmetry and atrophy patterns in temporal lobe epilepsy. Brain, 2022, 145, 1285-1298.	3.7	18
4	Nonâ€coding regulatory elements: Potential roles in disease and the case of epilepsy. Neuropathology and Applied Neurobiology, 2022, 48, .	1.8	14
5	Nonâ€Stationary Outcome of Alternating Hemiplegia of Childhood into Adulthood. Movement Disorders Clinical Practice, 2022, 9, 206-211.	0.8	1
6	Electroclinical Features and Long-term Seizure Outcome in Patients With Eyelid Myoclonia With Absences. Neurology, 2022, 98, .	1.5	15
7	A pharmacogenomic assessment of psychiatric adverse drug reactions to levetiracetam. Epilepsia, 2022, 63, 1563-1570.	2.6	11
8	SCN1A overexpression, associated with a genomic region marked by a risk variant for a common epilepsy, raises seizure susceptibility. Acta Neuropathologica, 2022, 144, 107-127.	3.9	3
9	161â€… Two-centre audit of cannabidiol use in adults with Dravet syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A59.2-A59.	0.9	0
10	Eventâ€based modeling in temporal lobe epilepsy demonstrates progressive atrophy from crossâ€sectional data. Epilepsia, 2022, 63, 2081-2095.	2.6	11
11	NEXMIF encephalopathy: an X-linked disorder with male and female phenotypic patterns. Genetics in Medicine, 2021, 23, 363-373.	1.1	28
12	Medullary tyrosine hydroxylase catecholaminergic neuronal populations in sudden unexpected death in epilepsy. Brain Pathology, 2021, 31, 133-143.	2.1	9
13	Precision medicine and therapies of the future. Epilepsia, 2021, 62, S90-S105.	2.6	39
14	Complex epilepsy: itâ€™s all in the history. Practical Neurology, 2021, 21, 153-156.	0.5	3
15	Clinical outcomes of COVID-19 in long-term care facilities for people with epilepsy. Epilepsy and Behavior, 2021, 115, 107602.	0.9	11
16	DOORS syndrome and a recurrentÂtruncating ATP6V1B2 variant. Genetics in Medicine, 2021, 23, 149-154.	1.1	11
17	Artificial intelligence for classification of temporal lobe epilepsy with ROI-level MRI data: A worldwide ENIGMA-Epilepsy study. NeuroImage: Clinical, 2021, 31, 102765.	1.4	25
18	PIGF deficiency causes a phenotype overlapping with DOORS syndrome. Human Genetics, 2021, 140, 879-884.	1.8	2

#	Article	IF	Citations
19	The impact of COVIDâ€19 in Dravet syndrome: A UK survey. Acta Neurologica Scandinavica, 2021, 143, 389-395.	1.0	7
20	1q21.1 distal copy number variants are associated with cerebral and cognitive alterations in humans. Translational Psychiatry, 2021, 11, 182.	2.4	24
21	Climate change and epilepsy: Insights from clinical and basic science studies. Epilepsy and Behavior, 2021, 116, 107791.	0.9	30
22	Increased facial asymmetry in focal epilepsies associated with unilateral lesions. Brain Communications, 2021, 3, fcab068.	1.5	5
23	Real-life survey of pitfalls and successes of precision medicine in genetic epilepsies. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1044-1052.	0.9	30
24	Assessing the role of rare genetic variants in drugâ€resistant, nonâ€lesional focal epilepsy. Annals of Clinical and Translational Neurology, 2021, 8, 1376-1387.	1.7	16
25	Regional microglial populations in central autonomic brain regions in SUDEP. Epilepsia, 2021, 62, 1318-1328.	2.6	15
26	Role of Common Genetic Variants for Drug-Resistance to Specific Anti-Seizure Medications. Frontiers in Pharmacology, 2021, 12, 688386.	1.6	6
27	The ENIGMA Toolbox: multiscale neural contextualization of multisite neuroimaging datasets. Nature Methods, 2021, 18, 698-700.	9.0	95
28	Largeâ€scale collaboration in ENIGMAâ€EEG: A perspective on the metaâ€analytic approach to link neurological and psychiatric liability genes to electrophysiological brain activity. Brain and Behavior, 2021, 11, e02188.	1.0	18
29	K.Vita: a feasibility study of a blend of medium chain triglycerides to manage drug-resistant epilepsy. Brain Communications, 2021, 3, fcab160.	1.5	17
30	Delineating the molecular and phenotypic spectrum of the SETD1B-related syndrome. Genetics in Medicine, 2021, 23, 2122-2137.	1.1	16
31	Carbon emission savings and shortâ€term health care impacts from telemedicine: An evaluation in epilepsy. Epilepsia, 2021, 62, 2732-2740.	2.6	31
32	Late diagnoses of Dravet syndrome: How many individuals are we missing?. Epilepsia Open, 2021, 6, 770-776.	1.3	9
33	Postictal Psychosis in Epilepsy: A Clinicogenetic Study. Annals of Neurology, 2021, 90, 464-476.	2.8	11
34	Cortical and Subcortical Network Dysfunction in a Female Patient With NEXMIF Encephalopathy. Frontiers in Neurology, 2021, 12, 722664.	1.1	3
35	4-Aminopyridine is a promising treatment option for patients with gain-of-function KCNA2 -encephalopathy. Science Translational Medicine, 2021, 13, eaaz4957.	5.8	40
36	Two-center experience of cannabidiol use in adults with Dravet syndrome. Seizure: the Journal of the British Epilepsy Association, 2021, 91, 5-8.	0.9	11

#	Article	IF	Citations
37	The impact of SARS-CoV-2 vaccination in Dravet syndrome: A UK survey. Epilepsy and Behavior, 2021, 124, 108258.	0.9	15
38	Structural brain imaging studies offer clues about the effects of the shared genetic etiology among neuropsychiatric disorders. Molecular Psychiatry, 2021, 26, 2101-2110.	4.1	53
39	Whole-genome sequencing: identification of additional pathogenic variation across the genome. Brain Communications, 2021, 3, fcab280.	1.5	0
40	Rare and Complex Epilepsies from Childhood to Adulthood: Requirements for Separate Management or Scope for a Lifespan Holistic Approach?. Current Neurology and Neuroscience Reports, 2021, 21, 65.	2.0	4
41	Meeting report: EpiXchange II brings together European epilepsy research projects to discuss latest advances. Epilepsy Research, 2021, 178, 106811.	0.8	1
42	Dose response of the 16p11.2 distal copy number variant on intracranial volume and basal ganglia. Molecular Psychiatry, 2020, 25, 584-602.	4.1	49
43	Epilepsy genetics and the precision medicine matrix. Lancet Neurology, The, 2020, 19, 29-30.	4.9	8
44	SUDEP: Advances and Challenges. Epilepsy Currents, 2020, 20, 29S-31S.	0.4	3
45	Moyamoya and progressive myoclonic epilepsy secondary to CLN6 bi-allelic mutations â€“ A previously unreported association. Epilepsy and Behavior Reports, 2020, 14, 100389.	0.5	4
46	Network-based atrophy modeling in the common epilepsies: A worldwide ENIGMA study. Science Advances, 2020, 6, .	4.7	97
47	Transcranial magnetic stimulation as a tool to understand genetic conditions associated with epilepsy. Epilepsia, 2020, 61, 1818-1839.	2.6	9
48	Cardiac phenotype in ATP1A3 -related syndromes. Neurology, 2020, 95, e2866-e2879.	1.5	19
49	Pharmacoresponse in genetic generalized epilepsy: a genome-wide association study. Pharmacogenomics, 2020, 21, 325-335.	0.6	21
50	Focal epilepsy in SCN1Aâ€mutation carrying patients: is there a role for epilepsy surgery?. Developmental Medicine and Child Neurology, 2020, 62, 1331-1335.	1.1	20
51	Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options. Pharmacological Reviews, 2020, 72, 606-638.	7.1	360
52	Testing association of rare genetic variants with resistance to three common antiseizure medications. Epilepsia, 2020, 61, 657-666.	2.6	22
53	Muscle and brain sodium channelopathies: genetic causes, clinical phenotypes, and management approaches. The Lancet Child and Adolescent Health, 2020, 4, 536-547.	2.7	13
54	The genetic architecture of the human cerebral cortex. Science, 2020, 367, .	6.0	450

#	Article	IF	Citations
55	Cardiac arrhythmias in Dravet syndrome: an observational multicenter study. Annals of Clinical and Translational Neurology, 2020, 7, 462-473.	1.7	11
56	Granule Cell Dispersion in Human Temporal Lobe Epilepsy: Proteomics Investigation of Neurodevelopmental Migratory Pathways. Frontiers in Cellular Neuroscience, 2020, 14, 53.	1.8	16
57	Valproate Use Is Associated With Posterior Cortical Thinning and Ventricular Enlargement in Epilepsy Patients. Frontiers in Neurology, 2020, 11, 622.	1.1	14
58	Pâ€glycoprotein overactivity in epileptogenic developmental lesions measured in vivo using (R)â€[11 C]verapamil PET. Epilepsia, 2020, 61, 1472-1480.	2.6	15
59	Neuropeptide depletion in the amygdala in sudden unexpected death in epilepsy: A postmortem study. Epilepsia, 2020, 61, 310-318.	2.6	14
60	Cortical myoclonus and epilepsy in a family with a new SLC20A2 mutation. Journal of Neurology, 2020, 267, 2221-2227.	1.8	5
61	The landscape of epilepsy-related GATOR1 variants. Genetics in Medicine, 2019, 21, 398-408.	1.1	137
62	Possible role of SCN4A skeletal muscle mutation in apnea during seizure. Epilepsia Open, 2019, 4, 498-503.	1.3	5
63	Ultra-Rare Genetic Variation in the Epilepsies: A Whole-Exome Sequencing Study of 17,606 Individuals. American Journal of Human Genetics, 2019, 105, 267-282.	2.6	237
64	Microbiota-gut brain axis involvement in neuropsychiatric disorders. Expert Review of Neurotherapeutics, 2019, 19, 1037-1050.	1.4	116
65	Comparative effectiveness of antiepileptic drugs in juvenile myoclonic epilepsy. Epilepsia Open, 2019, 4, 420-430.	1.3	34
66	Polygenic burden in focal and generalized epilepsies. Brain, 2019, 142, 3473-3481.	3.7	90
67	Characterisation of medullary astrocytic populations in respiratory nuclei and alterations in sudden unexpected death in epilepsy. Epilepsy Research, 2019, 157, 106213.	0.8	17
68	Intronic ATTTC repeat expansions in STARD7 in familial adult myoclonic epilepsy linked to chromosome 2. Nature Communications, 2019, 10, 4920.	5.8	99
69	Genomic and clinical predictors of lacosamide response in refractory epilepsies. Epilepsia Open, 2019, 4, 563-571.	1.3	12
70	Value of witness observations in the differential diagnosis of transient loss of consciousness. Neurology, 2019, 92, e895-e904.	1.5	27
71	Advancing research toward faster diagnosis, better treatment, and end of stigma in epilepsy. Epilepsia, 2019, 60, 1281-1292.	2.6	17
72	Late diagnosis of hypophosphatasia in a case with Unverricht-Lundborg disease. Annals of Clinical Biochemistry, 2019, 56, 515-518.	0.8	0

#	Article	IF	Citations
73	Why should a neurologist worry about climate change?. Lancet Neurology, The, 2019, 18, 335-336.	4.9	3
74	Diagnostic implications of genetic copy number variation in epilepsy plus. Epilepsia, 2019, 60, 689-706.	2.6	61
75	Hippocampal morphometry in sudden and unexpected death in epilepsy. Neurology, 2019, 93, e804-e814.	1.5	9
76	Drug-resistant epilepsy, early-onset hypertension and white matter lesions: a hidden paraganglioma. BMJ Case Reports, 2019, 12, e228348.	0.2	0
77	Climate change and epilepsy: Time to take action. Epilepsia Open, 2019, 4, 524-536.	1.3	4
78	Genetic architecture of subcortical brain structures in 38,851 individuals. Nature Genetics, 2019, 51, 1624-1636.	9.4	192
79	Re-annotation of 191 developmental and epileptic encephalopathy-associated genes unmasks de novo variants in SCN1A. Npj Genomic Medicine, 2019, 4, 31.	1.7	27
80	A new microdeletion syndrome involving TBC1D24, ATP6V0C, and PDPK1 causes epilepsy, microcephaly, and developmental delay. Genetics in Medicine, 2019, 21, 1058-1064.	1.1	22
81	Valproate and childbearing potential: new regulations. Practical Neurology, 2018, 18, 176-178.	0.5	17
82	The ventrolateral medulla and medullary raphe in sudden unexpected death in epilepsy. Brain, 2018, 141, 1719-1733.	3.7	80
83	Dysfunction of NaV1.4, a skeletal muscle voltage-gated sodium channel, in sudden infant death syndrome: a case-control study. Lancet, The, 2018, 391, 1483-1492.	6.3	63
84	Long-interval intracortical inhibition as biomarker for epilepsy: a transcranial magnetic stimulation study. Brain, 2018, 141, 409-421.	3.7	16
85	Structural brain abnormalities in the common epilepsies assessed in a worldwide ENIGMA study. Brain, 2018, 141, 391-408.	3.7	352
86	Genetic variation in CFH predicts phenytoin-induced maculopapular exanthema in European-descent patients. Neurology, 2018, 90, e332-e341.	1.5	43
87	Juvenile myoclonic epilepsy refractory to treatment in a tertiary referral center. Epilepsy and Behavior, 2018, 82, 81-86.	0.9	16
88	Pharmacogenomics in epilepsy. Neuroscience Letters, 2018, 667, 27-39.	1.0	109
89	Characterising subtypes of hippocampal sclerosis and reorganization: correlation with pre and postoperative memory deficit. Brain Pathology, 2018, 28, 143-154.	2.1	26
90	Nestinâ€expressing cell types in the temporal lobe and hippocampus: Morphology, differentiation, and proliferative capacity. Glia, 2018, 66, 62-77.	2.5	31

#	Article	IF	Citations
91	Ring Chromosome 17 Not Involving the Miller-Dieker Region: A Case with Drug-Resistant Epilepsy. Molecular Syndromology, 2018, 9, 38-44.	0.3	7
92	Neurologic phenotypes associated with COL4A1 / 2 mutations. Neurology, 2018, 91, e2078-e2088.	1.5	97
93	Personalized treatment in the epilepsies: challenges and opportunities. Expert Review of Precision Medicine and Drug Development, 2018, 3, 237-247.	0.4	3
94	De novo variants in neurodevelopmental disorders with epilepsy. Nature Genetics, 2018, 50, 1048-1053.	9.4	230
95	Analysis of shared heritability in common disorders of the brain. Science, 2018, 360, .	6.0	1,085
96	Doublecortin-expressing cell types in temporal lobe epilepsy. Acta Neuropathologica Communications, 2018, 6, 60.	2.4	28
97	Genomeâ€wide association study: Exploring the genetic basis for responsiveness to ketogenic dietary therapies for drugâ€resistant epilepsy. Epilepsia, 2018, 59, 1557-1566.	2.6	23
98	10.2174/1381612823666170809115827. Current Pharmaceutical Design, 2018, 23, 5667-5690.	0.9	9
99	ENIGMA and the individual: Predicting factors that affect the brain in 35 countries worldwide. NeuroImage, 2017, 145, 389-408.	2.1	173
100	Novel genetic loci associated with hippocampal volume. Nature Communications, 2017, 8, 13624.	5.8	250
101	Neuropathology of SUDEP. Neurology, 2017, 88, 551-561.	1.5	33
102	Temporary replacements for oral epilepsy treatments. Practical Neurology, 2017, 17, 4-5.	0.5	0
103	Spectral power changes prior to psychogenic non-epileptic seizures: a pilot study. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 190-192.	0.9	11
104	Haploinsufficiency for ANKRD11-flanking genes makes the difference between KBG and 16q24.3 microdeletion syndromes: 12 new cases. European Journal of Human Genetics, 2017, 25, 694-701.	1.4	33
105	Photosensitive epilepsy is associated with reduced inhibition of alpha rhythm generating networks. Brain, 2017, 140, 981-997.	3.7	45
106	An examination of biochemical parameters and their association with response to ketogenic dietary therapies. Epilepsia, 2017, 58, 893-900.	2.6	13
107	Familial childhood-onset progressive cerebellar syndrome associated with the ATP1A3 mutation. Neurology: Genetics, 2017, 3, e145.	0.9	15
108	Impaired intracortical inhibition demonstrated in vivo in people with Dravet syndrome. Neurology, 2017, 88, 1659-1665.	1.5	32

#	Article	IF	Citations
109	Histopathological Findings in Brain Tissue Obtained during Epilepsy Surgery. New England Journal of Medicine, 2017, 377, 1648-1656.	13.9	621
110	Comparative effectiveness of antiepileptic drugs in patients with mesial temporal lobe epilepsy with hippocampal sclerosis. Epilepsia, 2017, 58, 1734-1741.	2.6	26
111	Genome annotation for clinical genomic diagnostics: strengths and weaknesses. Genome Medicine, 2017, 9, 49.	3.6	51
112	Parental Origin of Interstitial Duplications at 15q11.2-q13.3 in Schizophrenia and Neurodevelopmental Disorders. PLoS Genetics, 2016, 12, e1005993.	1.5	51
113	Genetic and neurodevelopmental spectrum ofSYNGAP1-associated intellectual disability and epilepsy. Journal of Medical Genetics, 2016, 53, 511-522.	1.5	135
114	Novel genetic loci underlying human intracranial volume identified through genome-wide association. Nature Neuroscience, 2016, 19, 1569-1582.	7.1	213
115	Quantitative magnetic resonance imaging traits as endophenotypes for genetic mapping in epilepsy. NeuroImage: Clinical, 2016, 12, 526-534.	1.4	15
116	Value of patient-reported symptoms in the diagnosis of transient loss of consciousness. Neurology, 2016, 87, 625-633.	1.5	51
117	Mortality in Dravet syndrome: A review. Epilepsy and Behavior, 2016, 64, 69-74.	0.9	126
118	Early lipofuscin accumulation in frontal lobe epilepsy. Annals of Neurology, 2016, 80, 882-895.	2.8	24
119	De novo mutations ofKIAA2022in females cause intellectual disability and intractable epilepsy. Journal of Medical Genetics, 2016, 53, 850-858.	1.5	47
120	Advances in the development of biomarkers for epilepsy. Lancet Neurology, The, 2016, 15, 843-856.	4.9	283
121	Sudden unexpected death in epilepsy genetics: Molecular diagnostics and prevention. Epilepsia, 2016, 57, 17-25.	2.6	74
122	Retinal nerve fibre layer thinning is associated with drug resistance in epilepsy. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 396-401.	0.9	18
123	Audit of practice in sudden unexpected death in epilepsy (<scp>SUDEP</scp>) post mortems and neuropathological findings. Neuropathology and Applied Neurobiology, 2016, 42, 463-476.	1.8	68
124	Germline and somatic FGFR1 abnormalities in dysembryoplastic neuroepithelial tumors. Acta Neuropathologica, 2016, 131, 847-863.	3.9	143
125	Comorbidities of epilepsy: current concepts and future perspectives. Lancet Neurology, The, 2016, 15, 106-115.	4.9	453
126	Spontaneously Fluctuating Motor Cortex Excitability in Alternating Hemiplegia of Childhood: A Transcranial Magnetic Stimulation Study. PLoS ONE, 2016, 11, e0151667.	1.1	6

#	Article	IF	Citations
127	Genome-wide Polygenic Burden of Rare Deleterious Variants in Sudden Unexpected Death in Epilepsy. EBioMedicine, 2015, 2, 1063-1070.	2.7	74
128	Clinical profile of patients with ATP1A3 mutations in Alternating Hemiplegia of Childhoodâ€"a study of 155 patients. Orphanet Journal of Rare Diseases, 2015, 10, 123.	1.2	117
129	Multiphasic presentation of Rasmussen's encephalitis. Epileptic Disorders, 2015, 17, 315-320.	0.7	8
130	Favourable response to ketogenic dietary therapies: undiagnosed glucose 1 transporter deficiency syndrome is only one factor. Developmental Medicine and Child Neurology, 2015, 57, 969-976.	1.1	8
131	Diaphragm myoclonus followed by generalised atonia in a patient with trisomy 4p: unusual semiology in an unusual condition. Epileptic Disorders, 2015, 17, 473-477.	0.7	2
132	Faulty cardiac repolarization reserve in alternating hemiplegia of childhood broadens the phenotype. Brain, 2015, 138, 2859-2874.	3.7	30
133	Variants in KCNJ11 and BAD do not predict response to ketogenic dietary therapies for epilepsy. Epilepsy Research, 2015, 118, 22-28.	0.8	6
134	Common genetic variants influence human subcortical brain structures. Nature, 2015, 520, 224-229.	13.7	772
135	CHD2variants are a risk factor for photosensitivity in epilepsy. Brain, 2015, 138, 1198-1208.	3.7	112
136	Genetic screening and diagnosis in epilepsy?. Current Opinion in Neurology, 2015, 28, 136-142.	1.8	10
137	Structural imaging biomarkers of sudden unexpected death in epilepsy. Brain, 2015, 138, 2907-2919.	3.7	95
138	Genetic heterogeneity in Cornelia de Lange syndrome (CdLS) and CdLS-like phenotypes with observed and predicted levels of mosaicism. Journal of Medical Genetics, 2014, 51, 659-668.	1.5	141
139	Feverish prospects for seizure genetics. Nature Genetics, 2014, 46, 1255-1256.	9.4	8
140	The genetic basis of DOORS syndrome: an exome-sequencing study. Lancet Neurology, The, 2014, 13, 44-58.	4.9	108
141	Asystole in alternating hemiplegia with de novo ATP1A3 mutation. European Journal of Medical Genetics, 2014, 57, 37-39.	0.7	12
142	Ketogenic dietary therapies for adults with epilepsy: Feasibility and classification of response. Epilepsy and Behavior, 2014, 37, 77-81.	0.9	37
143	In vivo P-glycoprotein function before and after epilepsy surgery. Neurology, 2014, 83, 1326-1331.	1.5	37
144	Assessing parents' attitudes towards ketogenic dietary therapies. Epilepsy and Behavior, 2014, 39, 1-5.	0.9	9

#	Article	IF	Citations
145	Hippocampal subregion-specific microRNA expression during epileptogenesis in experimental temporal lobe epilepsy. Neurobiology of Disease, 2014, 62, 508-520.	2.1	163
146	International consensus classification of hippocampal sclerosis in temporal lobe epilepsy: A Task Force report from the <scp>ILAE</scp> Commission on Diagnostic Methods. Epilepsia, 2013, 54, 1315-1329.	2.6	816
147	Consensus on diagnosis and management of JME: From founder's observations to current trends. Epilepsy and Behavior, 2013, 28, S87-S90.	0.9	142
148	P-glycoprotein expression and function in patients with temporal lobe epilepsy: a case-control study. Lancet Neurology, The, 2013, 12, 777-785.	4.9	155
149	Regional thalamic neuropathology in patients with hippocampal sclerosis and epilepsy: A postmortem study. Epilepsia, 2013, 54, 2125-2133.	2.6	36
150	Neuropathology of the bloodâ€“brain barrier and pharmaco-resistance in human epilepsy. Brain, 2012, 135, 3115-3133.	3.7	117
151	HLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans. New England Journal of Medicine, 2011, 364, 1134-1143.	13.9	815
152	Genetic contribution to common epilepsies. Current Opinion in Neurology, 2011, 24, 140-145.	1.8	41
153	Investigation of widespread neocortical pathology associated with hippocampal sclerosis in epilepsy: A postmortem study. Epilepsia, 2011, 52, 10-21.	2.6	59
154	Dravet syndrome as epileptic encephalopathy: evidence from long-term course and neuropathology. Brain, 2011, 134, 2982-3010.	3.7	237
155	Genomics of drug resistance: moving ahead. Epilepsy and Seizure, 2010, 3, 59-64.	0.1	0
156	Focal cortical dysplasia type II: biological features and clinical perspectives. Lancet Neurology, The, 2009, 8, 830-843.	4.9	119
157	Genetics of antiepileptic drug resistance. Current Opinion in Neurology, 2009, 22, 150-156.	1.8	25
158	Brain structure, function, and genetics revealed by studies of the eye and face. Current Opinion in Neurology, 2008, 21, 404-409.	1.8	1
159	Etiology and management of refractory epilepsies. Nature Clinical Practice Neurology, 2007, 3, 320-330.	2.7	25
160	Genetic enhancement of cognition in a kindred with cone-rod dystrophy due to RIMS1 mutation. Journal of Medical Genetics, 2007, 44, 373-380.	1.5	29
161	Response to Janigro et al.. Epilepsia, 2007, 48, 1219-1220.	2.6	1
162	Multicentre search for genetic susceptibility loci in sporadic epilepsy syndrome and seizure types: a case-control study. Lancet Neurology, The, 2007, 6, 970-980.	4.9	175

#	Article	IF	Citations
163	Role of SOX2 Mutations in Human Hippocampal Malformations and Epilepsy. Epilepsia, 2006, 47, 534-542.	2.6	85
164	Genetics of Drug Resistance. Epilepsia, 2005, 46, 33-38.	2.6	23
165	Hippocampal Malformations Do Not Necessarily Evolve into Hippocampal Sclerosis. Epilepsia, 2005, 46, 939-943.	2.6	14
166	Genetics of drug resistance in epilepsy. Current Neurology and Neuroscience Reports, 2005, 5, 307-311.	2.0	9
167	Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 5507-5512.	3.3	321
168	Malformations of cortical development: burdens and insights from important causes of human epilepsy. Lancet Neurology, The, 2004, 3, 29-38.	4.9	166
169	Drug resistance in epilepsy: not futile, but complex?. Lancet Neurology, The, 2003, 2, 331.	4.9	8
170	Major Vault Protein, a Marker of Drug Resistance, Is Upregulated in Refractory Epilepsy. Epilepsia, 2003, 44, 1388-1396.	2.6	75
171	Widespread Upregulation of Drugâ€resistance Proteins in Fatal Human Statusâ€ƒEpilepticus. Epilepsia, 2003, 44, 261-264.	2.6	52
172	Mechanisms of antiepileptic drug resistance. Current Opinion in Neurology, 2003, 16, 197-201.	1.8	55
173	Abnormal expression of cdk5 in focal cortical dysplasia in humans. Neuroscience Letters, 2002, 328, 217-220.	1.0	23
174	Structural Image Analysis in Epilepsy. Epilepsia, 2002, 43, 19-24.	2.6	4
175	PAX6 haploinsufficiency causes cerebral malformation and olfactory dysfunction in humans. Nature Genetics, 2001, 28, 214-216.	9.4	220